Status:
COMPLETED
Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes
Lead Sponsor:
Steno Diabetes Center Copenhagen
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
40+ years
Phase:
PHASE4
Brief Summary
Aim: The United Kingdom Prospective Diabetes Study (UKPDS) showed a reduction in cardiovascular events in obese patients with type-2-diabetes treated with metformin compared with other hypoglycaemic ...
Detailed Description
After four months run-in with repaglinide plus metformin combination-therapy, patients with HemoglobinA1c ≥6.5% will be randomized (baseline=0 month) to repaglinide 2 mg thrice-daily or metformin 1g t...
Eligibility Criteria
Inclusion
- Non-obese patients (BMI \< 27 kg/m2)
- Type 2 diabetes
- Age 40 years or older
- HbA1c = 6.5% or higher at baseline.
Exclusion
- No known contraindications for either of the study-drugs (known allergy to the study-drugs; heart-, liver- or kidney-failure)
- Pregnancy
- Other serious physical or mental illnesses with a life-shortening prognosis.
- Drug or alcohol abuse.
- Weight-loss of more than 5 kg during the last 6 month prior to enrollment.
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2006
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT00118963
Start Date
January 1 2003
End Date
February 1 2006
Last Update
December 8 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Steno Diabetes Center
Gentofte Municipality, Denmark, 2820